With respect to the molecular classification of endometrial carcinomas (Soslow et al. 2019), uterine MLA show p53 wild-type immunostaining, retained mismatch-repair protein expression (see Fig. 1h–j) and are not associated with a POLE-mutation (Kolin et al. 2019; Horn et al. 2020; Ma et al. 2022; Deolet et al. 2021) defining them as endometrial carcinomas with no special molecular profile [NSMP (Horn et al. 2020; Deolet et al. 2021; McCluggage 2022)]. The gene discussed is TP53; the disease is endometrial carcinoma.